Guanze Medical Information Industry (Holding) Co., Ltd.

(Incorporated in the Cayman Islands with limited liability)

(Stock code：2427)

PROFIT WARNING

This announcement is made by Guanze Medical Information Industry (Holding) Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities (the "**Listing Rules**") on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") wishes to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on the preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026 and the information currently available, it is expected that the Group will record a loss attributable to owners of the Company of not more than RMB45.0 million for the six months ended 30 June 2026 as compared to the profit attributable to owners of the Company of approximately RMB3.4 million for the six months ended 30 June 2025. The Board considers that the expected loss was primarily attributable to: (i) a decrease in gross profit resulting from higher sales volumes of medical imaging film products and the provision of medical imaging cloud services, both of which have lower gross profit margins, together with a reduction in sales of software, which has a higher profit margin; (ii) an increase in depreciation expenses on property, plant and equipment allocated to cost of sales, administrative expenses and selling and distribution expenses; (iii) increased spending on research and development; and (iv) an increase in share-based payment expenses recognized upon the vesting of share awards in February 2026 as a result of the change in controlling shareholder.

The Company is still in the process of finalising the interim results of the Group for the six months ended 30 June 2026. The information contained in this announcement is only based on the preliminary assessment by the Board with reference to the information currently available to the Group and the unaudited consolidated management accounts of the Group for the six months ended 30 June 2026, which has not been audited or reviewed by the auditors or the audit committee of the Company and may be subject to adjustments. The Shareholders and potential investors are advised to read carefully the interim results announcement of the Company for the six months ended 30 June 2026, which is expected to be published on 31 August 2026.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Guanze Medical Information Industry (Holding) Co., Ltd.
Jiang Zeman
Chairman of the Board

Hong Kong, 26 August 2026

As at the date of this announcement, the executive Directors are Ms. Jiang Zeman, Ms. Qin Jingying and Mr. Meng Xianzhen, the independent non-executive Directors are Dr. Zhao Bin, Dr. Chang Shiwang and Dr. Wong Man Hin Raymond.